Image Source: Unsplash

An Introduction

This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies in the munKNEE Psychedelic Compound Based Clinical-Stage Drug Stocks Portfolio with their stock performances this week, in descending order, their areas of focus, and their latest news, analyses and commentary where available.

1. Mind Medicine (MNMD): up 15.6% this week; up 30.4% MTD; up 8.5% YTD
   • focuses on the use of LSD and MDMA. Go here for much more extensive information on LSD and here for much more extensive information on MDMA.
   • MindMed Announces Issuance of Patent For Drug To Treat Adults With Generalized Anxiety Disorder
2. GH Research (GHRS); up 11.5% this week; up 7.1% MTD; up 115.3% YTD
   • focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
3.  Compass Pathways (CMPS): up 9.1% this week; up 32.9% MTD; down 8.2% YTD
   • focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
4. atai Life Sciences (ATAI): up 6.9% this week; up 7.4% MTD; up 12.8% YTD
   • focuses on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.

Summary

On average, the above 4 stocks were up 13.5% this week, are up 20.1% MTD and up 60.6% YTD.

More By This Author:

Much Less Volatility Occurred In AI Stocks On Thursday
The AI/Tech Stock Selloff Is Overdone - It’s Time To Buy The Dip - Here's Why
Almost All AI Stocks Declined Sharply On Wednesday - Here's Why